Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

• 主要な著者: Xi Zhang (著者), Xiao Huo (著者), Hongyan Guo (著者), Lixiang Xue (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Tumors with BRCA1/2 mutations or homologous recombination repair defects are sensitive to PARP inhibitors through the mechanism of synthetic lethality. Several PARP inhibitors are currently approved for ovarian, breast and pancreatic cancer in clinical practice. However, more than 40% of patients wi...